--- title: "BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 | BCDA Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/285998512.md" description: "BioCardia, Inc. will host a conference call on May 15, 2026, at 4:30 PM EDT to discuss its Q1 2026 financial results and provide a corporate update. The call will include a Q&A session following management's remarks. Participants can register for the call and will receive dial-in information upon registration. The call will also be available via live webcast, with a replay accessible for a limited time afterward. BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases." datetime: "2026-05-11T13:10:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285998512.md) - [en](https://longbridge.com/en/news/285998512.md) - [zh-HK](https://longbridge.com/zh-HK/news/285998512.md) --- # BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 | BCDA Stock News SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. \[NASDAQ:BCDA\], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to: **https://dpregister.com/sreg/10209272/104069d5d88**. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Rt7kKGAp. A webcast replay of the call will be available approximately one hour after the end of the call through approximately August 15, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 4737992. **About BioCardia®** BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit www.biocardia.com. MEDIA CONTACT:Miranda Peto, Investor Relationsmpeto@biocardia.com(650) 226-0120INVESTOR CONTACT:David McClung, Chief Financial Officerinvestors@biocardia.com(650) 226-0120 ### Related Stocks - [BCDA.US](https://longbridge.com/en/quote/BCDA.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths](https://longbridge.com/en/news/286637684.md) - [BioCardia Q1 net loss narrows as expenses decline](https://longbridge.com/en/news/286562369.md) - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md) - [bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News](https://longbridge.com/en/news/286107351.md)